Evidence map›Paper›PMID 23629865›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2013

US valuation of the SF-6D.

Benjamin M Craig, A Simon Pickard, Elly Stolk, John E Brazier

Abstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Article
  12. The Utility of Erector Spinae Plane Blocks in Breast Surgery: A Practical Review.Plastic and reconstructive surgery. Global open · 2025
    Review
  13. The Short Form 6 Dimensions (SF-6D): Development and Evolution.Applied health economics and health policy · 2025
    Review
  14. Article
  15. Article
  16. Estimating Joint Health State Utility Algorithms Under Partial Information.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023
    Article
  17. Preferences of patients with chronic low back pain about nonsurgical treatments: Results of a discrete choice experiment.Health expectations : an international journal of public participation in health care and health policy · 2023
    Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benjamin M CraigHealth Outcomes & Behavior Program, Moffitt Cancer Center, Tampa, Florida (BMC)
A Simon PickardCenter for Pharmacoeconomic Research and Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois (ASP)
Elly StolkDepartment of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands (ES)
John E BrazierHealth Economics, Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK (JEB)

Funding

HRQoL Values for Cancer Survivors: Enhancing PROMIS Measures for CERR01CA160104 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI CRAIG, BENJAMIN M. · 2011 to 2015
$3.1M
Obesity, Aging, and Cancer Cost (OACC) StudyK25CA122176 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CRAIG, BENJAMIN M. · 2006 to 2010
$746k
NCI NIH HHS 1R01CA160104-01NCI NIH HHS K25 CA122176NCI NIH HHS K25-CA122176NCI NIH HHS R01 CA160104
6 · The paper itself

Abstract

backgroundThe original SF-6D valuation study collected 3503 standard gambled responses from 611 UK respondents to predict quality-adjusted life year (QALY) values.

methodsUsing 19,980 paired comparison responses from 666 US respondents and a stacked probit model, the 25 coefficients of the original SF-6D multiattribute utility (MAU) regression were estimated, such that each coefficient represents a QALY decrement. The US QALY predictions were compared with UK predictions using 8428 SF-6D states in the US Medicare Health Outcomes Survey (MHOS), 1998 to 2003.

resultsTwenty-two of the 25 decrements in the SF-6D MAU regression are statistically significant. The remaining decrements are insignificant based on US and UK results. The US and UK QALY predictions for the MHOS SF-6D states are remarkably similar given differences in experimental design, format, and sampling (Lin's coefficient of agreement, 0.941; absolute mean difference, 0.043). Limitations. The underlying theoretical framework for the STUDY

designand econometric analysis builds from the episodic random utility model and the concept of QALYs and inherits their limitations.

conclusionsThis study enhances the potential for US comparative effectiveness research by translating SF-6D states into US QALYs as well as improves upon discrete choice experiment design and econometric methods for health valuation.

Indexed as

Quality-Adjusted Life YearsHealth Status IndicatorsPsychometricsUnited Statesdecision analysiseconometric methodsmathematical modelspreferences and quality of lifestatistical methods

Identifiers

PMID23629865
PMCPMC3740344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.